Redhill Biopharma
RDHL
43 hedge funds and large institutions have $13.3M invested in Redhill Biopharma in 2022 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 13 increasing their positions, 13 reducing their positions, and 10 closing their positions.
42% more call options, than puts
Call options by funds: $368K | Put options by funds: $260K
6% more capital invested
Capital invested by funds: $12.5M → $13.3M (+$752K)
0% less ownership
Funds ownership: 0% → 0% (-0%)
0% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 13
16% less funds holding
Funds holding: 51 → 43 (-8)
80% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$2.04M |
| 2 |
BlackRock
New York
|
+$133K |
| 3 |
GS
Gagnon Securities
New York
|
+$116K |
| 4 |
VF
Virtu Financial
New York
|
+$64K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$37.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
II
Ibex Investors
Denver,
Colorado
|
-$675K |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$563K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$531K |
| 4 |
Millennium Management
New York
|
-$452K |
| 5 |
AGM
Alpine Global Management
New York
|
-$167K |
RDHL Hedge Fund Activity: Q1 2022 in Review
43 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Redhill Biopharma (RDHL) for Q1 2022, worth a combined $13.3M — up 6% from $12.5M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of RDHL and 2 opened new positions — a net loss of 8 holders — while 13 trimmed existing stakes and 13 added.
The largest buyer was ARK Investment Management, opening a new position worth an estimated $2.04M. The largest seller was Ibex Investors, exiting entirely with an estimated $675K sold.
- 43 institutional investors held Redhill Biopharma (RDHL) as of Q1 2022, down from 51 in Q4 2021.
- Funds reported $13.3M of Redhill Biopharma stock for Q1 2022, up 6% quarter-over-quarter.
- 2 funds opened new Redhill Biopharma positions in Q1 2022 and 10 closed out, a net change of -8 holders.
- The largest Redhill Biopharma buyer in Q1 2022 was ARK Investment Management, an estimated $2.04M added.
- The largest Redhill Biopharma seller in Q1 2022 was Ibex Investors, an estimated $675K sold.
Based on aggregated 13F filings for Q1 2022.